Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
120.60
+1.00 (+0.84%)
Official Closing Price
Updated: 4:10 PM EDT, Jun 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Today 10:05 EDT
Via
Investor Brand Network
The Quest to Repair What Multiple Sclerosis Takes Away
Today 10:05 EDT
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Today 9:55 EDT
Via
Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Today 9:48 EDT
Via
Investor Brand Network
Topics
Artificial Intelligence
The Quest to Repair What Multiple Sclerosis Takes Away
Today 8:30 EDT
From
BioMedWire
Via
GlobeNewswire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Today 8:30 EDT
From
BioMedWire
Via
GlobeNewswire
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Today 6:45 EDT
From
Merck & Co., Inc.
Via
Business Wire
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
June 22, 2026
From
Merck & Co., Inc.
Via
Business Wire
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
June 18, 2026
From
Merck & Co., Inc.
Via
Business Wire
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
June 17, 2026
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
June 12, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health to Acquire TARGAN
June 11, 2026
From
Merck & Co., Inc.
Via
Business Wire
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 08, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
June 08, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 02, 2026
From
Merck & Co., Inc.
Via
Business Wire
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
June 01, 2026
Via
ACCESS Newswire
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
May 29, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Jefferies Global Healthcare Conference
May 28, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Third-Quarter 2026 Dividend
May 26, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
May 22, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
May 18, 2026
From
Merck & Co., Inc.
Via
Business Wire
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026
Via
Investor Brand Network
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
May 13, 2026
Via
Investor Brand Network
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
May 12, 2026
From
Merck & Co., Inc.
Via
Business Wire
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026
From
BioMedWire
Via
GlobeNewswire
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
May 07, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
May 06, 2026
From
Salesforce
Via
Business Wire
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 05, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
April 30, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
April 28, 2026
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
